





ELIGARD[®]

leuprorelin acetate



The only subcutaneous ADT injection available in 4 dosing options¹



1 month | 7.5 mg
5 repeats
12 injections per year

3 month | 22.5 mg
1 repeat
4 injections per year

4 month | 30 mg
1 repeat
3 injections per year

6 month | 45 mg
0 repeats
2 injections per year



EFFICACY^{1,2}

Mean serum testosterone suppression to **<0.44 nmol/L across all doses**



SUBCUTANEOUS ADMINISTRATION¹

Short needle length (1.59 cm) and small injection volume (<0.5 mL)



FLEXIBLE DOSING OPTIONS¹

1, 3, 4 and 6 months

Abbreviation: ADT = androgen deprivation therapy.

PBS Information: Restricted Benefit. Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate.

Please review the Product Information before prescribing. Product Information can be accessed via www.mundipharma.com.au/products or via the QR code.

Adverse events should be reported. Reporting forms and information can be found at <https://aems.tga.gov.au/>. Adverse events should also be reported to drugsafety@mundipharma.com.au

Reference: 1. ELIGARD[®] Approved Product Information, Jul 2022. 2. Shore ND, *et al.* BJU Int 2017;119(2):239-44.

